Pfizer stock edged lower early Wednesday after the pharmaceutical giant reported adjusted income of $1.07 per share on $19 billion in second-quarter sales.
In the year-earlier period, Pfizer earned 78 cents per share and reported $11.8 billion in sales.
The $19 billion in sales includes some $7.9 billion related to its coronavirus vaccine with BioNTech (BNTX).
For the year, Pfizer guided to adjusted EPS of $3.95-$4.05 with revenue of $78 billion to $80 billion. That’s largely due to the Covid vaccine. Pfizer now sees coronavirus vaccine revenue of $33.5 billion vs. its old target of $26 billion.
Analysts expected $3.71 earnings per share and $72.53 billion in sales.
More to follow.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE: